Imunon, Inc. (IMNN) - 10-K Filing Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2025. Imunon, Inc. is a clinical-stage biotechnology company developing non-viral DNA therapeutics. Its primary focus is IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer, which is currently in a Phase 3 clinical trial (OVATION 3). The company also developed IMNN-101, a COVID-19 booster vaccine, though development of this program has been paused pending partnership opportunities.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(14.5) million | $(18.6) million |
| Research & Development Expenses | $7.8 million | $11.6 million |
| General & Administrative Expenses | $6.9 million | $7.5 million |
| Cash and Cash Equivalents (Year End) | $8.8 million | $5.9 million |
| Accumulated Deficit | $(421.3) million | $(406.8) million |
| Net Cash Used in Operating Activities | $(13.9) million | $(18.9) million |
Note: The company has no product revenue and does not expect to generate revenue in the near term.
Material Changes vs. Prior Period
- Reduced Net Loss: The net loss decreased by approximately $4.1 million (22%) compared to 2024, driven primarily by a 33% reduction in R&D expenses.
- R&D Spend Shift: R&D expenses dropped significantly due to the completion of the Phase 1 PlaCCine vaccine trial (costs fell from $1.4M to $10k) and reduced spending on the OVATION 2 trial. However, costs for the new Phase 3 OVATION 3 trial began in 2025 ($1.3M).
- Capital Raising: The company raised approximately $24.9 million in gross proceeds through equity offerings in 2025, including a July 2024 offering, a May 2025 private placement, and a December 2025 registered direct offering.
- Corporate Actions: The company executed a 15-for-1 reverse stock split in July 2025 and issued a 15% stock dividend in August 2025.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has determined there is substantial doubt about the company's ability to continue as a going concern for the next twelve months. The independent auditor has included an explanatory paragraph regarding this uncertainty. The company's cash balance of $8.8 million is insufficient to fund operations for the next year without additional financing.
- Clinical Outlook:
- IMNN-001 (Ovarian Cancer): Final data from the Phase 2 OVATION 2 study showed a median 14.7-month increase in overall survival compared to standard of care. The Phase 3 OVATION 3 trial is ongoing with enrollment ahead of forecast.
- IMNN-101 (Vaccine): Phase 1 data showed safety and immunogenicity, but the company has paused further development of this study to seek partnerships.
- Financing Needs: The company plans to raise additional capital through equity offerings (including its ATM program) or strategic partnerships. Failure to secure funding could force the company to delay or terminate clinical trials.
- Regulatory Risks: The company faces risks related to FDA approval timelines, manufacturing compliance, and the potential for clinical trial failure.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $8.8 million cash balance against current burn rates and the timeline for the Phase 3 trial completion.
- Dilution Risk: Review the terms of recent equity offerings (May and December 2025) and the impact of outstanding warrants (approx. 4.5 million) on future dilution.
- Clinical Milestones: Monitor enrollment rates and interim data releases for the Phase 3 OVATION 3 trial, which is critical for regulatory approval.
- Partnership Status: Confirm if any strategic partnerships or licensing deals have been secured for the IMNN-101 vaccine program to offset development costs.
- Going Concern Mitigation: Assess the feasibility of management's plan to raise capital in the current market environment.